Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

The 'big three' insulin producers Novo Nordisk ... including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people - and much more ...

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...

Meanwhile Novo Nordisk has also seen its ranking surge ... Download the Productive Innovation Index white paper here. About the author: Andrew McConaghie is pharmaphorum's managing editor, feature ...

The University of California system was sued on Monday by a student group for alleged racial discrimination in admissions by favoring Black and ... 2025 Novo Nordisk agreed to cap insulin prices ...

Novo Nordisk agreed to cap insulin prices to settle ... is returning to private legal practice after his wife's failed White House bid, joining corporate law firm Willkie Farr & Gallagher.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...